【レポートの概要（一部）】
1 Table of Contents
1 Table of Contents 10
1.1 List of Tables 17
1.2 List of Figures 25
2 Introduction 28
2.1 Catalyst 28
2.2 Related Reports 29
2.3 Upcoming Related Reports 29
3 Disease Overview 30
3.1 Etiology and Pathophysiology 30
3.1.1 Etiology 30
3.1.2 Pathophysiology 30
3.2 Symptoms 35
3.3 Prognosis 36
3.4 Quality of Life 36
4 Epidemiology 37
4.1 Disease Background 37
4.2 Risk Factors and Comorbidities 37
4.3 Global Trends 39
4.3.1 US 39
4.3.2 5EU 40
4.3.3 Japan 41
4.3.4 Australia 41
4.3.5 China 42
4.3.6 India 42
4.4 Forecast Methodology 42
4.4.1 Sources Used 45
4.4.2 Sources Not Used 49
4.4.3 Forecast Assumptions and Methods – Total Prevalent Cases of RA 50
4.4.4 Forecast Assumptions and Methods – Diagnosed Prevalent Cases of RA 54
4.5 Epidemiological Forecast for RA (2013-2023) 55
4.5.1 Total Prevalent Cases of RA 55
4.5.2 Age-Specific Total Prevalent Cases of RA 57
4.5.3 Sex-Specific Total Prevalent Cases of RA 59
4.5.4 Diagnosed Prevalent Cases of RA 61
4.5.5 Age-Standardized Diagnosed Prevalence of RA 63
4.6 Discussion 65
4.6.1 Epidemiological Forecast Insight 65
4.6.2 Limitations of the Analysis 65
4.6.3 Strengths of the Analysis 66
5 Disease Management 67
5.1 Diagnosis and Treatment Overview 67
5.1.1 Diagnosis 67
5.1.2 Treatment Guidelines 69
5.1.3 Leading Prescribed Drugs for the Treatment of RA 78
5.1.4 Clinical Practice 79
5.2 US 84
5.3 France 88
5.4 Germany 89
5.5 Italy 92
5.6 Spain 94
5.7 UK 95
5.8 Japan 99
5.9 Australia 101
5.10 China 103
5.11 India 105
6 Competitive Assessment 108
6.1 Overview 108
6.2 Product Profiles – Major Brands 109
6.2.1 Enbrel (etanercept) 109
6.2.2 Humira (adalimumab) 116
6.2.3 Remicade (infliximab) 120
6.2.4 Simponi (golimumab) 126
6.2.5 Cimzia (certolizumab pegol) 132
6.2.6 Orencia (abatacept) 136
6.2.7 Actemra/RoActemra (tocilizumab) 142
6.2.8 Rituxan/MabThera (rituximab) 150
6.2.9 Inflectra/Remsima (infliximab biosimilar) 155
6.2.10 Xeljanz (tofacitinib) 158
6.2.11 Iguratimod/T-614 165
6.2.12 Methotrexate (Numerous Brands) 169
6.3 Biosimilars 172
6.3.1 Introduction 172
6.3.2 Hospira’s Inflectra Versus J&J’s Remicade in Key Autoimmune Diseases 174
6.3.3 Biosimilars in the Immunology Community 174
6.3.4 By the Numbers: Biosimilars in Development 175
6.3.5 The Impact of Biosimilars Will be Felt Throughout the Pharmaceutical Industry 179
6.3.6 Uptake of Biosimilars for RA is Expected to Vary by Market 180
6.3.7 Biosimilars’ Forecast 183
6.4 Other Therapies 191
7 Unmet Need and Opportunity 193
7.1 Overview 193
7.2 Development of Cost-Effective Therapies 194
7.2.1 Unmet Need 194
7.2.2 Gap Analysis 195
7.2.3 Opportunity 195
7.3 Biomarkers to Predict Responsiveness to Therapy 196
7.3.1 Unmet Need 196
7.3.2 Gap Analysis 198
7.3.3 Opportunity 198
7.4 Early Diagnosis of RA 199
7.4.1 Unmet Need 199
7.4.2 Gap Analysis 200
7.4.3 Opportunity 201
7.5 Personalized Treatment Approach 202
7.5.1 Unmet Need 202
7.5.2 Gap Analysis 202
7.5.3 Opportunity 204
8 Pipeline Assessment 206
8.1 Overview 206
8.2 Clinical Trial Mapping 206
8.2.1 Clinical Trials by Class 206
8.3 Promising Drugs in Clinical Development 208
8.3.1 Sarilumab 215
8.3.2 Sirukumab 223
8.3.3 Clazakizumab 230
8.3.4 Cosentyx (secukinumab) 236
8.3.5 Tregalizumab 242
8.3.6 Mavrilimumab 248
8.3.7 Denosumab (Prolia/Xgeva) 253
8.3.8 Baricitinib 259
8.3.9 Peficitinib 269
8.3.10 Decernotinib 275
8.3.11 Filgotinib 281
8.3.12 Masitinib 287
8.3.13 RAVAX 294
8.4 Other Drugs in Development 299
9 Current and Future Players 302
9.1 Trends in Corporate Strategy 305
9.2 Company Profiles 306
9.2.1 AbbVie 306
9.2.2 Pfizer 308
9.2.3 Amgen 311
9.2.4 Johnson & Johnson 314
9.2.5 Eli Lilly 316
9.2.6 Bristol-Myers Squibb 318
9.2.7 UCB 320
9.2.8 Roche 321
9.2.9 GlaxoSmithKline 323
9.2.10 Novartis 325
9.2.11 Sanofi 327
9.2.12 AstraZeneca- MedImmune 329
9.2.13 Astellas 331
9.2.14 Vertex 333
9.2.15 Daiichi Sankyo 335
10 Market Outlook 338
10.1 Global Markets 338
10.1.1 Forecast 338
10.1.2 Drivers and Barriers – Global Issues 343
10.2 United States 345
10.2.1 Forecast 345
10.2.2 Key Events 351
10.2.3 Drivers and Barriers 352
10.3 France 354
10.3.1 Forecast 354
10.3.2 Key Events 359
10.3.3 Drivers and Barriers 359
10.4 Germany 362
10.4.1 Forecast 362
10.4.2 Key Events 367
10.4.3 Drivers and Barriers 368
10.5 Italy 371
10.5.1 Forecast 371
10.5.2 Key Events 376
10.5.3 Drivers and Barriers 376
10.6 Spain 378
10.6.1 Forecast 378
10.6.2 Key Events 384
10.6.3 Drivers and Barriers 385
10.7 United Kingdom 387
10.7.1 Forecast 387
10.7.2 Key Events 393
10.7.3 Drivers and Barriers 393
10.8 Japan 396
10.8.1 Forecast 396
10.8.2 Key Events 401
10.8.3 Drivers and Barriers 401
10.9 Australia 404
10.9.1 Forecast 404
10.9.2 Key Events 409
10.9.3 10.9.3 Drivers and Barriers 409
10.10 China 411
10.10.1 Forecast 411
10.10.2 Key Events 416
10.10.3 Drivers and Barriers 416
10.11 India 418
10.11.1 Forecast 418
10.11.2 Key Events 423
10.11.3 Drivers and Barriers 423
11 Appendix 426
11.1 Bibliography 426
11.2 Abbreviations 452
11.3 Methodology 459
11.4 Forecasting Methodology 459
11.4.1 Diagnosed RA Patients 459
11.4.2 Percentage of Drug-Treated Patients 460
11.4.3 Drugs Included in Each Therapeutic Class 460
11.4.4 Launch and Patent Expiry Dates 461
11.4.5 General Pricing Assumptions 462
11.4.6 Individual Drug Assumptions 464
11.4.7 Generic and Biosimilar Erosion 476
11.4.8 Pricing of Pipeline Agents 476
11.5 Primary Research – KOLs Interviewed for This Report 479
11.6 Primary Research – Prescriber Survey 481
11.7 About the Authors 481
11.7.1 Analyst 481
11.7.2 Reviewer 482
11.7.3 Therapy Area Director 482
11.7.4 Epidemiologist 483
11.7.5 Global Head of Healthcare 484
11.8 About GlobalData 485
11.9 Disclaimer 485
【レポート販売概要】
■ タイトル：関節リウマチ（Rheumatoid Arthritis）治療薬の世界市場予測および分析■ 英文：PharmaPoint: Rheumatoid Arthritis - Global Drug Forecast and Market Analysis to 2023
■ 発行日：2014年12月31日
■ 調査会社：GlobalData
■ 商品コード：GDHC93PIDR
■ 調査対象地域：グローバル
- 世界のビックデータ市場：機会、課題、戦略、産業、予測“Big Data” originally emerged as a term to describe datasets whose size is beyond the ability of traditional databases to capture, store, manage and analyze. However, the scope of the term has significantly expanded over the years. Big Data not only refers to the data itself but also a set of technologies that capture, store, manage and analyze large and variable collections of data to solve compl …
- ノロウイルスワクチン（Norovirus vaccine）の世界市場機会分析Noroviruses (NVs) called "Norwalk-like viruses" are a group of single-stranded positive sense RNA viruses and members of the family Caliciviridae. NVs are transmitted from human-to-human and are one of the most highly infectious viruses known. In the community, NVs most commonly cause a self-limiting mild disease of short duration with gastrointestinal symptoms usually resolving after 1 to 3 days. …
- 免疫タンパク質検査の世界市場2015During the next decade, the immunoprotein testing market will undergo significant transformation. The changes will be caused by convergence of new and more stringent regulations; advances in diagnostic technologies, system engineering, automation, and IT; and intensifying competition. Some segments will start resembling commodity markets, where product positioning and cost per test are more critic …
- Gliosarcoma：グローバル臨床試験レビューH2, 2013Gliosarcoma Global Clinical Trials Review, H2, 2013 Summary GlobalData's clinical trial report, “Gliosarcoma Global Clinical Trials Review, H2, 2013" provides data on the Gliosarcoma clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Gliosarcoma. It includes an overview of the trial numbers and their recruitment status as per the site of …
- 変電所自動化の世界市場2015-2019About substation automation Substation automation is the upgrade or improvement of existing electrical substations. This includes incorporation of intelligent technologies and equipment, such as relational databases and advanced communication systems, into power grids. Automation of substations help electric utilities monitor and control the T and D processes of substations remotely, thus, ensurin …
- コーティング織物の世界市場分析：製品別（ポリマー、ゴム、布張り壁コーティング）、用途別（輸送、防護服、工業用、家具）、セグメント予測、-2020The global market for coated fabrics is expected to reach USD 22,576.7 million by 2020, according to a new study by Grand View Research, Inc. Coated fabrics market is expected to witness rapid growth due to positive outlook on application markets and product innovation. Increasing growth in automotive industry is also expected to boost the coated fabrics market over the forecast period. Rising dem …
- スパの世界市場：デイ/クラブ・スパ、ホテル/リゾート・スパ、デスティネーション・スパ、メディカル・スパAbout Spa Market With increasingly hectic lifestyles and a rise in healthcare costs, many people are looking for ways to get and stay healthy. Spas offer a way for people to jump start a good and healthy lifestyle and there are multiple options for consumers to choose. The decision to go to a specific spa could stem from reasons like needing to get away or even due to doctor’s orders. Spas are a g …
- 胃酸過多/胸やけ/呑酸(Acid Indigestion / Heartburn/ Pyrosis)：世界の治験レビュー（2015年上半期版）Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2015 Summary GlobalData's clinical trial report, “Acid Indigestion / Heartburn/ Pyrosis Global Clinical Trials Review, H1, 2015" provides data on the Acid Indigestion / Heartburn/ Pyrosis clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Acid Indigestion / Heartbur …
- 世界の船舶用コーティング市場動向（2014-2018）TechNavio's analysts forecast the Global Marine Coatings market to grow at a CAGR of 11.29 percent over the period 2013-2018. One of the key factors contributing to this market growth is the expansion of the Oil and Gas market. The Global Marine Coatings market has also been witnessing the growing consumer preference for eco-friendly products; however, the strict environmental regulations could po …
- クラウド・コラボレーション・ソリューションの世界市場：ECM、DSM、プロジェクト管理、ソーシャル・コラボレーション、UCCCloud collaboration is a new method of sharing the documents and computer related files where they can be accessed by others through cloud computing. The cloud collaboration solution has enabled the users to collaborate, comment, share, and upload the files or documents within the cloud. With the help of cloud collaboration users can work together and connect with partners, customers, and employee …
- アンチセンス及びRNAi治療の世界市場About Antisense and RNAi Therapeutics Antisense and RNAi therapeutics are new innovative therapeutics options that are used in the treatment of serious chronic and rare diseases. RNAi is a RNA-based gene silencing process in which RNA molecules inhibit gene expression by destructing definite mRNA molecules. Antisense technology involves the synthesis of a strand of nucleic acid that would bind to …
- 電池管理システム（BMS）の世界市場：リチウムイオン電池、鉛電池、フロー電池、ニッケル電池The battery management system market was valued at USD 1.98 Billion in 2015 and is expected to reach USD 7.25 Billion by 2022, at a CAGR of 20.5% between 2016 and 2022. The growth of this market is propelled by the rapidly growing need for battery management system given the increasing number of vehicles that require charging such as electric vehicles (EVs), hybrid electric vehicles (HEVs), and pl …
- 敗血症(Septicaemia)：世界の治験レビュー2014年下半期版Septicaemia Global Clinical Trials Review, H2, 2014 Summary GlobalData's clinical trial report, “Septicaemia Global Clinical Trials Review, H2, 2014" provides data on the Septicaemia clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Septicaemia. It includes an overview of the trial numbers and their recruitment status as per the site of …
- ワークフォース分析の世界市場2015-2022According to Stratistics MRC, the Global Workforce Analytics market is accounted for $439.4 million in 2015 and is expected to reach $1.29 billion by 2022 growing at a CAGR of 16.7% from 2015 to 2022. Workforce analytics is a combination of software and methodology that implements statistical models to employee related data. The driving factor for workforce analytics market is competition within t …
- LED（発光ダイオード）の世界市場：一般照明用、自動車ライト用、バックライト用About the LED Market LED lights are rapidly gaining traction among consumers due to their multiple benefits. They are preferred over other lights such as incandescent lights and compact fluorescent lights (CFLs), because of their energy efficiency. LEDs consume up to 75% less energy than other bulbs and have longer lifespans — 60,000 hours compared to 1,500 hours from incandescent bulbs and 8,000 …
